Check Your Article For Submission

Copyright
Reviewing And Promptness Of Publication

MANUSCRIPT SUBMISSION:

An online submission and tracking service via the Internet facilitates a speedy and cost-effective submission of manuscripts. The full manuscript has to be proposed online via Lifescience Global Canada Inc. Processing Management System (PMS) Manuscript Processing System (PMS) https://www.lifescienceglobal.com/pms/.

Please submit your paper in MS Word (.doc or .docx / LaTeX) file format according to the detailed Manuscript Preparation Guides given below. The number of pages is at the authors' discretion; on average, papers are 10-25 pages long. When developing your article for publication, we firmly advise that you pay particular care to your research methods, key results, and language. To ensure rapid review and publication, please adhere to these guidelines.

It is imperative that before submission, authors should carefully proofread the files for special characters, mathematical symbols, Greek letters, equations, tables, and images, to ensure that they emerge in the proper format.

References, figures, tables, structures, etc., should be noted in the text where they have been discussed. The author also should present figure legends/captions. 

Originality:

Submissions must be original work, the copyright to which is not earlier published elsewhere. Originality, creativity, and a cross-disciplinary method or perspectives are greatly encouraged. Striking duplication of papers and conforming submissions are not allowed. In such cases, the Publisher owns the right to withdraw publishing rights from authors and co-authors of the article for an actual-time—possible copyright dispute with the copyright holder and consent to our Link to Publication Ethics and Malpractice Statement. Publication Ethics and Publication Malpractice Statement. For detailed please visit: PUBLISHING ETHICS AND INTEGRITY

Language:

Given that the manuscript must be drafted in English by the author, and if English is not the author's origin tongue, we recommend that the paper be proofed to assure its efficiency and develop the language class. The Publisher can also provide a copy-editing service free of cost.

COPYRIGHT:

Authors who publish in Lifescience Global Canada Inc. journals retain copyright to their work. Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Covering Letter or the Terms and Conditions. It is a condition of publication that manuscripts submitted to a journal have not been published and will not be simultaneously submitted or published elsewhere.

Lifescience Global Canada Inc. (Licensor) grants the author(s) a worldwide, royalty-free, non-exclusive, and non-commercial perpetual license to exercise the rights in the article published as stated below:

• All articles are published under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/legalcode), which permits free distribution and reproduction in any medium that the work is properly cited.
• The authors retain the copyright of their published Open Access article. They will also have the right to:
• Reproduce the article, to incorporate the article into one or more collective works, and to reproduce the article as incorporated in collective works;
• Create and reproduce Derivative Works for educational purposes.
• Distribute Copies
• Any commercial application of the work, with prior agreement by the author, is exclusively granted to Lifescience Global Canada Inc. 

Download Copyright Form

Manuscript Preparation:

Manuscripts presented for research and review articles in the respective journal should be split into the following sections:

• Title
• Title Page
• Structured Abstract
• Keywords
• Text Aim
• Conclusion
• List of Abbreviations (if any)
• Approval for Publication
• Availability of Data and Materials
• Funding
• Conflict of Interest
• Acknowledgments
• References
• Appendices
• Figures/Illustrations (if any)
• Chemical Structures (if any)
• Tables (if any)
• Supportive/Supplementary Material (if any)

Title:

The title should be specific and concise and must not be more than 130 words. 

Title Page:

The title page should combine article title, author (s) full name and affiliation, corresponding author(s) names absolute affiliation/address, along with phone, fax, and e-mail.

As recommended by the Reporting guidelines, information about the study should be a part of the title (especially for randomized or clinical trials, detailed reviews, and meta-analyses).

Authors should also present a short 'running title'. The title, running title, line correspondent footnote, and keywords should be rewritten as shown in the original manuscript.

Structured Abstract:

An article's abstract should be its clear, concise, and precise summary, should no more than 250 words, and include the specific sub-headings (as in-line or run-in headings in bold). 

The headings can adjust but must state the purpose of the study, details of the members, measurements, methods, principal verdicts, and conclusion.

Keywords:

The author must provide 6 to 8 keywords. Keep important and relevant keywords that researchers in your field will attempt so that your article will emerge in a database search. The keywords should be contained in the title, and they should appear many times in the article. In biomedical disciplines, MeSH terms are a large 'common vocabulary' reference to draw keywords from https://www.nlm.nih.gov/mesh/meshhome.html.

Text Aim:

The main text should begin on a separate page and split into the title, abstract, and main text. The text may be subdivided further according to the fields to be discussed, backed by the List of Abbreviations (if any), Conflict of Interest, Acknowledgements, and Reference sections. For Review Articles, the manuscript should be prepared into title page, abstract, and the main text. The text may be partitioned further according to the fields to remain explained, accompanied by the Acknowledgements and Reference sections. The Review Article should discuss any previous notable current and old reviews in the area and contain a broad discussion starting with the general background of the field. It should then move on to discuss the remarkable features of recent developments. The authors should bypass presenting material that has already been declared in a former review. The authors are advised to show and discuss their observations in summary. Non-assimilated terms from Latin or other languages should be italicized, e.g., per se et al., etc.

For Research Articles, the manuscript should begin with the title page and abstract followed by the main text, which needs to be structured into separate sections as Introduction, Materials and Methods, Results, Discussion, Conclusion, Ethics Approval, and Consent to Participate, Human and Animal Rights, Conflict of Interest, Acknowledgements, and References.

All randomized clinical investigations must include a flow diagram, and authors should give a completed randomized trial checklist (see CONSORT Flow Diagram and Checklist; www.consort-statement.org) and a test protocol.

For case reports, the authors should follow the CARE guidelines. The CARE checklist should be performed as a separate file.

The full term for an abbreviation should introduce its first appearance in the text, except it is a standard unit of measurement. The reference numbers should be given in square brackets in the text. Italics should be done for Binomial names of organisms (Genus and Species) for emphasis and unfamiliar words or phrases. 

Introduction:

The Introduction section should include the background and aims of the research comprehensively.

Materials and Methods:

This section provides details of the methodology used along with information on any previous efforts with corresponding references. The author should include any details for further modifications and research. Sufficient information should be provided to the reader about the original data source to enable the analysis, appropriateness, and verification of the results reported in the study.

The Method Section needs to be sufficiently detailed regarding the data presented and the results produced from it. This section should include all the information and protocol gathered for the study when it was being communicated. If the assignment is funded or financially supported by an organization to conduct the research, it should be considered in the Method Section. Methods must be result-oriented. The statement regarding the approval by an independent local, regional or national review committee (e.g., the ethics committee and institutional review board) should be part of the Methods Section.

Experimental:

The author should not report repeated information in the text of an article. A calculation section must include experimental data, facts, and practical development from a theoretical perspective.

Results:

The essential and main findings of the study should come first in the Results Section. The tables, figures, and references should be given in sequence to emphasize the vital information or observations related to the research. The author should avoid the repetition of data in tables and figures. Results should be precise.

Discussion:

The author should explore the significance of the results of the work and present a reproducible procedure. The author should avoid extensive citations and discussion of published literature.

The Results and discussions may be presented separately or combined in a single section with short and informational headings.

Conclusion:

The author may give a small paragraph summarising the article's contents, presenting the research outcome, or proposing further study on the subject at the end of the article under the Conclusion section.

Funding:

The authors need to declare the funding sources of their manuscripts clearly by providing the name of the funding agency or financial support along with allotted grant/award number in round brackets (if applied), for instance, 

"This work was financially supported by [name of the funding agency] (Grant number XXX).

Similarly, if a paper does not have any particular funding source, and is part of the profession of the authors, then the name of the employer will be expected. Authors will have to state that the funder was involved in writing, editing, approval, or decision to publish the article.

Greek Symbols and Special Characters:

Greek symbols and special characters often undergo formatting changes and get corrupted or lost while preparing a manuscript for publication. 

Authors are encouraged to consult reporting guidelines. These guidelines give a set of recommendations comprising a list of items relevant to their specific research design.

List of Abbreviations (if any):

If abbreviations are used in the text either, they should be specified in the text where first used, or the author should provide a list of abbreviations.

Appendixes:

If there is a need to present lengthy but essential methodological details, use appendices, which can be a part of the article. An individual appendix should be titled APPENDIX, while more extra than one can be titled APPENDIX A, APPENDIX B, and so on.

Supportive/Supplementary Material (if any):

Supportive/Supplementary material intended for publication must be numbered and referred to in the manuscript but should not be a part of the submitted paper. The author should provide In-text citations and a section with the heading "Supportive/Supplementary Material" before the "References" section. 

Research Ethics and Policies

Conflict of Interest:

The author must acknowledge financial contributions and any possible conflict of interest under the heading 'Conflict of Interest'. Authors need to list the source(s) of funding for the research. 

Acknowledgments:

All individuals listed as authors must have devoted substantially to the conception, execution, analysis, or summarising of the work and are required to indicate their particular contribution. Anyone (individual/company/institution) who has substantially contributed to studying important intellectual content or was involved in drafting or revising the manuscript must also be acknowledged.

Guest or honorary authorship based solely on position (e.g., research supervisor, departmental head) is discouraged.

The specific conditions for authorship have been established by the International Committee of Medical Journal Editors (http://www.icmje.org/). 

Human and Animal Rights:

The author should conduct all clinical investigations according to the Declaration of Helsinki principles. For all manuscripts reporting data from studies involving human participants, formal review and approval by an appropriate institutional review board or ethics committee are required.

For research involving animals, the authors should indicate whether the procedures followed the standards outlined in the eighth edition of "Guide for the Care and Use of Laboratory Animals" (grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals_prepub.pdf published by the National Academy of Sciences, The National Academies Press, Washington, D.C.).

Research Involving Animals:

Research work on animals should be carried out by the NC3Rs ARRIVE Guidelines. For In Vivo Experiments, please visit https://www.nc3rs.org.uk/arrive-guidelines.

Authors should clearly state the name of the approval committee, highlighting that the author obtained legal and ethical approvals before initiation of the research work carried out on animals and that the experiments were conducted following the relevant guidelines and regulations stated below.

• US authors should cite compliance with the US National Research Council's "Guide for the Care and Use of Laboratory Animals."
• The US Public Health Service's "Policy on Humane Care and Use of Laboratory Animals" and "Guide for the Care and Use of Laboratory Animals."
• UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039).
• European authors outside the UK should conform to Directive 2010/63/EU.
• Research on animals should adhere to ethical guidelines of The Basel Declaration and the International Council for Laboratory Animal Science (ICLAS) ethical guidelines.
• The manuscript should include a declaration of compliance with the relevant guidelines (e.g., the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or applicable permits or licenses obtained by the IUCN Policy Statement on Research Involving Species at Risk of Extinction and the Convention on the Trade in Endangered Species of Wild Fauna and Flora.

Research Involving Plants:

All experimental research on plants (either cultivated or wild) should comply with international guidelines. The manuscript should add a declaration of compliance of field studies with appropriate procedures and/or relevant permissions or licenses obtained by the IUCN Policy Statement on Research Involving Species at Risk of Extinction and the Convention on the Trade in Endangered Species of Wild Fauna and Flora.

Patient Consent:

Compliance with the guidelines of the International Committee of Medical Journal Editors www.icmje.org) is recommended, following the patient's consent for research or participation in a study as per the applicable laws and regulations regarding the privacy and/or security of personal information, including, but not limited to, the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") and other U.S. federal and state laws relating to confidentiality and security of personally distinguishable evidence, the General Data Protection Regulation (GDPR) (EU) 2016/679 and member state implementing legislation, Canada's Personal Information Protection and Electronic Documents Act, India's Information Technology Act and related Privacy Rules, (together "Data Protection and Privacy Laws").

It is the liability of the author to ensure that:

• Patients' names, initials, or hospital numbers are not defined in the manuscript (including figures).
• Authors are liable for securing the patient consent-to-disclose forms for all recognizable subjects in photographs, videos, or other information that may be published in the journal, in derivative works, or on the journal's website and for providing the manuscript to the recognizable patient for review before submission.
• The consent-to-disclose form should indicate specific use (publication in the medical literature in print and online, understanding that patients and the public will have access) of the patient's information and images in figures or videos. 
• All such case reports require proper consent to be taken before publishing.

Editors may ask that authors provide documentation of the previous review and support from the institutional review board or ethics committee responsible for oversight of the study. The editors reserve the liberty to reject manuscripts that do not comply with the requirements mentioned above.

Unethical Behavior:

Anyone may point out unethical behavior and misconduct to the Editor and Publisher with enough shreds of evidence. In consultation with the Publisher, the Editor will initiate an investigation against this Unethical misconduct, complete the procedure until an unbiased decision is reached, and maintain confidentiality throughout the research process. The author should be allowed to reply to all minor or major accusations.

In case of serious breaches, the employer may be informed by the publishers, where appropriate, by the Editor/Publisher, after reviewing all available information and shreds of evidence or seeking help from experts in that field.

Consent for Publication:

If the manuscript has individuals' data, such as personal detail, audio-video material, etc., the author's consent should be taken by the individual. In children's cases, permission should be obtained from the parent or the legal guardian.

Declaration of Gen AI Use in STM Publications

The guidelines below are only for the writing process, not for using AI tools to analyze and draw insights from data as part of the research process.

When using generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should use these tools only to enhance readability and language. Human oversight and control are necessary when applying the technology, and authors should thoroughly review and edit the result. It's important to note that AI can produce output that sounds authoritative but may be incorrect, incomplete, or biased. AI and AI-assisted technologies should not be credited as authors or co-authors, nor should they be cited as such. Authorship entails responsibilities and tasks that are unique to and can only be carried out by humans.

Authors must disclose their use of AI and AI-assisted technologies in their manuscript preparation by following the instructions. A statement regarding this disclosure will be included in the published work. It is important to note that authors bear full responsibility for the content of their work.

Disclosure Instructions

Please ensure that any use of generative AI and AI-assisted technologies in the writing process is disclosed by adding a statement at the end of the manuscript in the core manuscript file before the References list. This statement should be placed in a new section titled 'Declaration of Generative AI and AI-assisted technologies in the writing process'.

Statement: During the preparation of this work, the author(s) utilized [NAME OF TOOL/SERVICE] to [REASON]. Following this tool/service, the author(s) reviewed and edited the content as necessary and take(s) full responsibility for the publication's content.

This declaration does not apply to basic tools for checking grammar, spelling, and references. There is no need to include a statement if there is nothing to disclose.

References:

The author should submit preferably in the Vancouver style. All references must be complete and accurate. The references should be relevant to the study and should refer to the original research sources. The authors, editors, and peer-reviewers should avoid Self-citation and self-interest.

Below are a few examples of references listed in the Vancouver Style:

Vancouver Style

All references should be numbered sequentially [in square brackets] in the text and listed in the same numerical order in the reference section in Vancouver style. Punctuation should be appropriately applied, as mentioned in the examples given above.

Reference Lists:

Different reference formats have different citation rules. See below for some basic format standards.

Journal Article

The required information for a journal article is the author's name, abbreviated journal title, year, publication, volume number, and initial page of cited article, though full pagination is reasonable. It is essential to list all authors if the total number of authors is six or less, and for more than six authors, use three authors and then et al. (the term "et al." should be in italics). Journal abbreviations should follow the Index Medicus/MEDLINE. The author must capitalize the first letter of the first word in the title. The rest of the title should be in lower-case, except for proper names.

[1]     Smith SD, Jones, AD. Organ donation. N Engl J Med 2001; 657: 230-5.

[2]     Brown JG. Asphyxiation. Med J Aust 2003; 432:120-4.

Typical Chapter Reference:

[3]     Blaxter PS, Farnsworth TP. Social health and class inequalities. In: Carter C, Peel JR, editors. Equalities and inequalities in health. 2nd ed. London: Academic Press 1976; p. 165-78.

Book Reference:

[4]     Carlson BM. Human embryology and developmental biology. 3rd ed. St. Louis: Mosby; 2004.

Edited Book:

[5]     Brown AM, Stubbs DW, Eds. Medical physiology. New York: Wiley 1983.

Conference Paper and Proceedings:

[6]     Anderson JC. Current status of chorion villus biopsy. In: Tudenhope D, Chenoweth J, editors. Proceedings of the 4th Congress of the Australian Perinatal Society; 1986: Brisbane, Queensland: Australian Perinatal Society; 1987: p. 190-6.

[7]     Harris AH, Editor. Economics and health: 1997: Proceedings of the 19th Australian Conference of Health Economists; 1997: Sep 13-14; Sydney, Australia. Kensington, N.S.W.: School of Health Services Management, University of New South Wales; 1998.

Journal Article on the Internet:

[8]     Aylin P, Bottle A, Jarman B, Elliott, P. Paediatric cardiac surgical mortality in England after Bristol: descriptive analysis of hospital episode statistics 1991-2002. BMJ [serial on the Internet]. 2004 Oct 9;[cited 2004 October 15]; 329:[about 10 screens]. Available from: https://www.bmj.com/content/329/7470/825.full

Book/Monograph on the Internet: 

[9]     Dungworth D, Editor. Iron Age and Roman Copper Alloys from Northern Britain [monograph on the Internet]. Washington: Digital Monograph Series; [cited 1997]: Available from https://intarch.ac.uk/journal/issue2/dungworth_index.html.

Web site/Homepage:

[10]   Aylin P, Bottle A, Jarman B, Elliott, P. Paediatric cardiac surgical mortality in England after Bristol: descriptive analysis of hospital episode statistics 1991-2002. BMJ [serial on the Internet]. 2004 Oct 9; [cited: 15 October 2004]; 329: [about 10 screens]. Available from: sis.nlm.nih.gov/Tox/ToxMain.html.

Journal with Part/Supplement:

If a journal carries continuous pagination throughout the volume, then the issue number can be omitted.

Issue with Supplement:

[11]   Glauser TA. Integrating clinical trial data into clinical practice. Neurology 2002; 58(12 Suppl 7): S6-12.

Volume with Part:

[12]   Abend SM, Kulish N. The psychoanalytic method from an epistemological viewpoint. Int J Psychoanal 2002; 83(Pt 2): 491-5.

Issue with Part:

[13]   Ahrar K, Madoff DC, Gupta S, Wallace MJ, Price RE, Wright KC. Development of a large animal model for lung tumours. J Vasc Interv Radiol 2002; 13(9 Pt 1): 923-8.

Patent:

[14]   Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug.

E-citations:

[15]   Citations for articles/material published exclusively online or in open access (free-to-view) must contain the exact Web addresses (URLs) at the end of the reference(s), except those posted on an author's Web site unless editorially essential, e.g. 'Reference: Available from: URL'.

Figures / Tables / Illustrations (if any):

The authors are expected to submit good-quality figure(s) in PDF, PPT, MS Word, TIFF, or JPEG versions.

Requirement

• Width = 8.5 inches (In-between the required size)
• Height = 11 inches (In-between the required size)

All figures should be in vector scale (except half tone, photograph.)

Chemical Structures:

Chemical structures MUST be prepared in ChemDraw/CDX and provided as a separate file.

Tables:

Data Tables should be submitted in Microsoft Word or Excel format.

• Each table should include a title/caption explaining the details discussed in the table. Detailed legends may then follow.
• Table number in bold font, i.e., Table 1, should follow a title. The title should be in small case with the first letter in caps. 
• Columns and rows of data should be made visibly distinct by ensuring that the borders of each cell are performed as black lines.
• Tables should be numbered in Arabic numerals sequentially in order of their citation in the body of the text.
• Reference cited in both the table and text, please insert a lettered footnote to refer to the numbered reference in the text.
• It is adequate to present data in Tables to avoid unnecessary repetition and reduce the length of the text.
• The author must ensure the citation of each table in the text.
• The author should explain symbols and non-standard abbreviations at the end of the text.
• All references should be numbered sequentially [in square brackets] in the table and listed in the same numerical order in the reference section.

LANGUAGE AND EDITING:

Manuscripts containing language inconsistencies will not be published. Authors should seek professional assistance for correcting grammatical, scientific, and typographical errors before submitting the revised version of the article for publication. 

PROOF CORRECTIONS:

Authors are required to proofread the PDF versions of their manuscripts before submission. To avoid delays in publication, proofs should be checked immediately for typographical errors and returned within 48 hours. 

The corresponding author will be entirely responsible for assuring that the revised version of the manuscript, including all the proposed amendments, permits the endorsement of all the authors of the manuscript.

REVIEWING AND PROMPTNESS OF PUBLICATION

All papers submitted for publication are immediately subjected to preliminary editorial scrutiny by the Editor-in-Chief regarding their suitability. The Editor-in-Chief determines if the manuscript:

• Falls within the scope of the journal and
• Meets the editorial criteria of Lifescience Global Canada Inc. in terms of originality and quality.

Manuscripts that appear suitable are then subjected to double-blind peer-review by, usually three, neutral eminent experts. The services of well-known international experts are sought through invitations to peer-review a submitted manuscript, keeping in view the manuscript's scope and the reviewers' expertise. The anonymity of reviewers ensures objective and unbiased assessment of the manuscript by the reviewers.

Before sending the manuscripts to reviewers, Lifescience Global Canada Inc. asks for consent from potential reviewers about their availability and willingness to review. Correspondence between the editorial office of the journal and the reviewers is kept confidential. The reviewers are expected to provide their reports in a timely fashion since a prompt review leads to the timely publication of a manuscript that is beneficial not only to the authors but also to the scientific community.

The editorial process and peer-review workflow for each journal are taken care of by a team of Senior Editors, Editorial Board Members (EBMs), and dedicated Journal managers who have the required expertise in their specific fields.

Lifescience Global Canada Inc. carries out an independent review of all articles. The reviewers are chosen according to their expertise from our regularly updated referee database.

The Editors may recommend acceptance, revision, or rejection of a manuscript based on reviewer comments.

Reviewer's comments may be categorized as:

• Requires minor changes
• Requires major changes
• Rejected but may be resubmitted
• Rejected with no resubmission

Lifescience Global Canada Inc. requests not to have the manuscripts peer-reviewed by those experts who may have a competing interest with the author(s) of a submitted manuscript. Editors can't be aware of all competing interests; therefore, it is assumed that the reviewers would inform the Editor-in-Chief/Handling Editor if they notice any potential competing interest during the review of a manuscript.

The authors are usually requested to resubmit the revised paper within five days, and it will then be returned to the reviewers for further evaluation by the publishers. The Editor-in-Chief of the journal is the final authority to accept or reject the manuscript.

• The average time during which the preliminary assessment of manuscripts is conducted is 5 Days
• The average time during which the reviews of manuscripts are conducted 45 Days
• The average time in which the article is published 60 Days

PUBLICATION CHARGES POLICY: 

Lifescience Global Canada Inc. is committed to disseminating research and scholarly publications as widely as possible. It supports the principle that 'the study results that have been publicly funded should be freely accessible in the public domain. Therefore, it encourages researchers to make their research available through Open Access (OA).

Open access publishing is not without costs. Lifescience Global Canada Inc. provides open access publications partly pay the expenses of journal production, online hosting, and archiving from authors and their research supporters by charging a publication fee for each article they publish. For further details please visit: PUBLICATION CHARGES.

SPECIAL FEE WAIVERS:

Lifescience Global Canada Inc. offers waivers and discounts to those corresponding authors: who are based in low-income countries. 

50% FEE concession to authors from any of the below countries, which the World Bank classified as Low-income economies as of 2021. For further details please visit FEE WAIVERS

PLAGIARISM PREVENTION

Lifescience Global Canada Inc. practices the iThenticate software, which detects instances of overlapping and similar text in submitted manuscripts. This software controls content against a database of periodicals, the Internet, and an extensive article database. It generates a similarity report, highlighting the percentage overlap between the uploaded article and the published material. For further details please visit: PLAGIARISM PREVENTION

Lifescience Global Canada Inc. strictly follows the COPE guidelines to detect plagiarism; for more clear insight, authors may refer to flowcharts provided by COPE.

APPEALS AND COMPLAINTS:

Generally, the editorial decisions are not reverted. Authors who think that their manuscript was rejected due to a misunderstanding or mistake may seek an explanation for the decision. Appeals must give sound reasoning and compelling evidence against the criticism raised in the rejection letter. A difference of opinion, interest, novelty, or suitability of the manuscript for the journal will not be recognized as an appeal. The EIC and other relevant editors will consider the request, and the decision after that taken by the journal will be deemed final. Acceptance of the manuscript is not guaranteed even if the journal agrees to reconsider the manuscript. The reconsideration process may involve previous or new reviewers or editors and substantive revision.

Authors who wish to make a complaint should refer them to the Editor-in-Chief of the journal concerned. Lifescience Global Canada Inc. is constantly striving to improve its publication practices. If you are not satisfied with any procedure of the processing of your manuscript, then please let us know at the following e-mail address with full details:

For assistance, please contact: This email address is being protected from spambots. You need JavaScript enabled to view it.. For complaints, please contact: This email address is being protected from spambots. You need JavaScript enabled to view it..

REPRINTS:

Lifescience Global Canada Inc. provides excellent professionally printed reprints. The minimum limit of reprint order is 100 copies.

PRINTED COVERS:

Printed covers are available at extra cost.

For further details, please visit: This email address is being protected from spambots. You need JavaScript enabled to view it.

PERMISSION FOR REPRODUCTION:

Published/reproduced material should not be included unless you have obtained written permission from the copyright holder. 

For obtaining permission for reproducing any material published in an article by Lifescience Global Canada Inc. This email address is being protected from spambots. You need JavaScript enabled to view it. for consideration.

CONFERENCE PROCEEDINGS:

For proposals to publish conference proceedings in this journal, please contact us at e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it..

Check Your Article For Submission

Download Article's Template

Copyright
Reviewing And Promptness Of Publication

MANUSCRIPT SUBMISSION:

An online submission and tracking service via the Internet facilitates a speedy and cost-effective submission of manuscripts. The full manuscript has to be proposed online via Lifescience Global Canada Inc. Processing Management System (PMS) Manuscript Processing System (PMS) https://www.lifescienceglobal.com/pms/.

Please submit your paper in MS Word (.doc or .docx / LaTeX) file format according to the detailed Manuscript Preparation Guides given below. The number of pages is at the authors' discretion; on average, papers are 10-25 pages long. When developing your article for publication, we firmly advise that you pay particular care to your research methods, key results, and language. To ensure rapid review and publication, please adhere to these guidelines.

It is imperative that before submission, authors should carefully proofread the files for special characters, mathematical symbols, Greek letters, equations, tables, and images, to ensure that they emerge in the proper format.

References, figures, tables, structures, etc., should be noted in the text where they have been discussed. The author also should present figure legends/captions. 

Originality:

Submissions must be original work, the copyright to which is not earlier published elsewhere. Originality, creativity, and a cross-disciplinary method or perspectives are greatly encouraged. Striking duplication of papers and conforming submissions are not allowed. In such cases, the Publisher owns the right to withdraw publishing rights from authors and co-authors of the article for an actual-time—possible copyright dispute with the copyright holder and consent to our Link to Publication Ethics and Malpractice Statement. Publication Ethics and Publication Malpractice Statement. For detailed please visit: PUBLISHING ETHICS AND INTEGRITY

Language:

Given that the manuscript must be drafted in English by the author, and if English is not the author's origin tongue, we recommend that the paper be proofed to assure its efficiency and develop the language class. The Publisher can also provide a copy-editing service free of cost.

COPYRIGHT:

Authors who publish in Lifescience Global Canada Inc. journals retain copyright to their work. Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Covering Letter or the Terms and Conditions. It is a condition of publication that manuscripts submitted to a journal have not been published and will not be simultaneously submitted or published elsewhere.

Lifescience Global Canada Inc. (Licensor) grants the author(s) a worldwide, royalty-free, non-exclusive, and non-commercial perpetual license to exercise the rights in the article published as stated below:

• All articles are published under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/legalcode), which permits free distribution and reproduction in any medium that the work is properly cited.
• The authors retain the copyright of their published Open Access article. They will also have the right to:
• Reproduce the article, to incorporate the article into one or more collective works, and to reproduce the article as incorporated in collective works;
• Create and reproduce Derivative Works for educational purposes.
• Distribute Copies
• Any commercial application of the work, with prior agreement by the author, is exclusively granted to Lifescience Global Canada Inc. 

Download Copyright Form

Manuscript Preparation:

Manuscripts presented for research and review articles in the respective journal should be split into the following sections:

• Title
• Title Page
• Structured Abstract
• Keywords
• Text Aim
• Conclusion
• List of Abbreviations (if any)
• Approval for Publication
• Availability of Data and Materials
• Funding
• Conflict of Interest
• Acknowledgments
• References
• Appendices
• Figures/Illustrations (if any)
• Chemical Structures (if any)
• Tables (if any)
• Supportive/Supplementary Material (if any)

Title:

The title should be specific and concise and must not be more than 130 words. 

Title Page:

The title page should combine article title, author (s) full name and affiliation, corresponding author(s) names absolute affiliation/address, along with phone, fax, and e-mail.

As recommended by the Reporting guidelines, information about the study should be a part of the title (especially for randomized or clinical trials, detailed reviews, and meta-analyses).

Authors should also present a short 'running title'. The title, running title, line correspondent footnote, and keywords should be rewritten as shown in the original manuscript.

Structured Abstract:

An article's abstract should be its clear, concise, and precise summary, should no more than 250 words, and include the specific sub-headings (as in-line or run-in headings in bold). 

The headings can adjust but must state the purpose of the study, details of the members, measurements, methods, principal verdicts, and conclusion.

Keywords:

The author must provide 6 to 8 keywords. Keep important and relevant keywords that researchers in your field will attempt so that your article will emerge in a database search. The keywords should be contained in the title, and they should appear many times in the article. In biomedical disciplines, MeSH terms are a large 'common vocabulary' reference to draw keywords from https://www.nlm.nih.gov/mesh/meshhome.html.

Text Aim:

The main text should begin on a separate page and split into the title, abstract, and main text. The text may be subdivided further according to the fields to be discussed, backed by the List of Abbreviations (if any), Conflict of Interest, Acknowledgements, and Reference sections. For Review Articles, the manuscript should be prepared into title page, abstract, and the main text. The text may be partitioned further according to the fields to remain explained, accompanied by the Acknowledgements and Reference sections. The Review Article should discuss any previous notable current and old reviews in the area and contain a broad discussion starting with the general background of the field. It should then move on to discuss the remarkable features of recent developments. The authors should bypass presenting material that has already been declared in a former review. The authors are advised to show and discuss their observations in summary. Non-assimilated terms from Latin or other languages should be italicized, e.g., per se et al., etc.

For Research Articles, the manuscript should begin with the title page and abstract followed by the main text, which needs to be structured into separate sections as Introduction, Materials and Methods, Results, Discussion, Conclusion, Ethics Approval, and Consent to Participate, Human and Animal Rights, Conflict of Interest, Acknowledgements, and References.

All randomized clinical investigations must include a flow diagram, and authors should give a completed randomized trial checklist (see CONSORT Flow Diagram and Checklist; www.consort-statement.org) and a test protocol.

For case reports, the authors should follow the CARE guidelines. The CARE checklist should be performed as a separate file.

The full term for an abbreviation should introduce its first appearance in the text, except it is a standard unit of measurement. The reference numbers should be given in square brackets in the text. Italics should be done for Binomial names of organisms (Genus and Species) for emphasis and unfamiliar words or phrases. 

Introduction:

The Introduction section should include the background and aims of the research comprehensively.

Materials and Methods:

This section provides details of the methodology used along with information on any previous efforts with corresponding references. The author should include any details for further modifications and research. Sufficient information should be provided to the reader about the original data source to enable the analysis, appropriateness, and verification of the results reported in the study.

The Method Section needs to be sufficiently detailed regarding the data presented and the results produced from it. This section should include all the information and protocol gathered for the study when it was being communicated. If the assignment is funded or financially supported by an organization to conduct the research, it should be considered in the Method Section. Methods must be result-oriented. The statement regarding the approval by an independent local, regional or national review committee (e.g., the ethics committee and institutional review board) should be part of the Methods Section.

Experimental:

The author should not report repeated information in the text of an article. A calculation section must include experimental data, facts and practical development from a theoretical perspective.

Results:

The essential and main findings of the study should come first in the Results Section. The tables, figures, and references should be given in sequence to emphasize the vital information or observations related to the research. The author should avoid the repetition of data in tables and figures. Results should be precise.

Discussion:

The author should explore the significance of the results of the work and present a reproducible procedure. The author should avoid extensive citations and discussion of published literature.

The Results and discussions may be presented separately or combined in a single section with short and informational headings.

Conclusion:

The author may give a small paragraph summarising the article's contents, presenting the research outcome, or proposing further study on the subject at the end of the article under the Conclusion section.

Funding:

The authors need to declare the funding sources of their manuscripts clearly by providing the name of the funding agency or financial support along with allotted grant/award number in round brackets (if applied), for instance, 

"This work was financially supported by [name of the funding agency] (Grant number XXX).

Similarly, if a paper does not have any particular funding source, and is part of the profession of the authors, then the name of the employer will be expected. Authors will have to state that the funder was involved in writing, editing, approval, or decision to publish the article.

Greek Symbols and Special Characters:

Greek symbols and special characters often undergo formatting changes and get corrupted or lost while preparing a manuscript for publication. 

Authors are encouraged to consult reporting guidelines. These guidelines give a set of recommendations comprising a list of items relevant to their specific research design.

List of Abbreviations (if any):

If abbreviations are used in the text either, they should be specified in the text where first used, or the author should provide a list of abbreviations.

Appendixes:

If there is a need to present lengthy but essential methodological details, use appendices, which can be a part of the article. An individual appendix should be titled APPENDIX, while more extra than one can be titled APPENDIX A, APPENDIX B, and so on.

Supportive/Supplementary Material (if any):

Supportive/Supplementary material intended for publication must be numbered and referred to in the manuscript but should not be a part of the submitted paper. The author should provide In-text citations and a section with the heading "Supportive/Supplementary Material" before the "References" section. 

Research Ethics and Policies

Conflict of Interest:

The author must acknowledge financial contributions and any possible conflict of interest under the heading 'Conflict of Interest'. Authors need to list the source(s) of funding for the research. 

Acknowledgments:

All individuals listed as authors must have devoted substantially to the conception, execution, analysis, or summarising of the work and are required to indicate their particular contribution. Anyone (individual/company/institution) who has substantially contributed to studying important intellectual content or was involved in drafting or revising the manuscript must also be acknowledged.

Guest or honorary authorship based solely on position (e.g., research supervisor, departmental head) is discouraged.

The specific conditions for authorship have been established by the International Committee of Medical Journal Editors (http://www.icmje.org/). 

Human and Animal Rights:

The author should conduct all clinical investigations according to the Declaration of Helsinki principles. For all manuscripts reporting data from studies involving human participants, formal review and approval by an appropriate institutional review board or ethics committee are required.

For research involving animals, the authors should indicate whether the procedures followed the standards outlined in the eighth edition of "Guide for the Care and Use of Laboratory Animals" (grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals_prepub.pdf published by the National Academy of Sciences, The National Academies Press, Washington, D.C.).

Research Involving Animals:

Research work on animals should be carried out by the NC3Rs ARRIVE Guidelines. For In Vivo Experiments, please visit https://www.nc3rs.org.uk/arrive-guidelines.

Authors should clearly state the name of the approval committee, highlighting that the author obtained legal and ethical approvals before initiation of the research work carried out on animals and that the experiments were conducted following the relevant guidelines and regulations stated below.

• US authors should cite compliance with the US National Research Council's "Guide for the Care and Use of Laboratory Animals."
• The US Public Health Service's "Policy on Humane Care and Use of Laboratory Animals" and "Guide for the Care and Use of Laboratory Animals."
• UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039).
• European authors outside the UK should conform to Directive 2010/63/EU.
• Research on animals should adhere to ethical guidelines of The Basel Declaration and the International Council for Laboratory Animal Science (ICLAS) ethical guidelines.
• The manuscript should include a declaration of compliance with the relevant guidelines (e.g., the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or applicable permits or licenses obtained by the IUCN Policy Statement on Research Involving Species at Risk of Extinction and the Convention on the Trade in Endangered Species of Wild Fauna and Flora.

Research Involving Plants:

All experimental research on plants (either cultivated or wild) should comply with international guidelines. The manuscript should add a declaration of compliance of field studies with appropriate procedures and/or relevant permissions or licenses obtained by the IUCN Policy Statement on Research Involving Species at Risk of Extinction and the Convention on the Trade in Endangered Species of Wild Fauna and Flora.

Patient Consent:

Compliance with the guidelines of the International Committee of Medical Journal Editors www.icmje.org) is recommended, following the patient's consent for research or participation in a study as per the applicable laws and regulations regarding the privacy and/or security of personal information, including, but not limited to, the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") and other U.S. federal and state laws relating to confidentiality and security of personally distinguishable evidence, the General Data Protection Regulation (GDPR) (EU) 2016/679 and member state implementing legislation, Canada's Personal Information Protection and Electronic Documents Act, India's Information Technology Act and related Privacy Rules, (together "Data Protection and Privacy Laws").

It is the liability of the author to ensure that:

• Patients' names, initials, or hospital numbers are not defined in the manuscript (including figures).
• Authors are liable for securing the patient consent-to-disclose forms for all recognizable subjects in photographs, videos, or other information that may be published in the journal, in derivative works, or on the journal's website and for providing the manuscript to the recognizable patient for review before submission.
• The consent-to-disclose form should indicate specific use (publication in the medical literature in print and online, understanding that patients and the public will have access) of the patient's information and images in figures or videos. 
• All such case reports require proper consent to be taken before publishing.

Editors may ask that authors provide documentation of the previous review and support from the institutional review board or ethics committee responsible for oversight of the study. The editors reserve the liberty to reject manuscripts that do not comply with the requirements mentioned above.

Unethical Behavior:

Anyone may point out unethical behavior and misconduct to the Editor and Publisher with enough shreds of evidence. In consultation with the Publisher, the Editor will initiate an investigation against this Unethical misconduct, complete the procedure until an unbiased decision is reached, and maintain confidentiality throughout the research process. The author should be allowed to reply to all minor or major accusations.

In case of serious breaches, the employer may be informed by the publishers, where appropriate, by the Editor/Publisher, after reviewing all available information and shreds of evidence or seeking help from experts in that field.

Consent for Publication:

If the manuscript has individuals' data, such as personal detail, audio-video material, etc., the author's consent should be taken by the individual. In children's cases, permission should be obtained from the parent or the legal guardian.

Declaration of Gen AI Use in STM Publications

The guidelines below are only for the writing process, not for using AI tools to analyze and draw insights from data as part of the research process.

When using generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should use these tools only to enhance readability and language. Human oversight and control are necessary when applying the technology, and authors should thoroughly review and edit the result. It's important to note that AI can produce output that sounds authoritative but may be incorrect, incomplete, or biased. AI and AI-assisted technologies should not be credited as authors or co-authors, nor should they be cited as such. Authorship entails responsibilities and tasks that are unique to and can only be carried out by humans.

Authors must disclose their use of AI and AI-assisted technologies in their manuscript preparation by following the instructions. A statement regarding this disclosure will be included in the published work. It is important to note that authors bear full responsibility for the content of their work.

Disclosure Instructions

Please ensure that any use of generative AI and AI-assisted technologies in the writing process is disclosed by adding a statement at the end of the manuscript in the core manuscript file before the References list. This statement should be placed in a new section titled 'Declaration of Generative AI and AI-assisted technologies in the writing process'.

Statement: During the preparation of this work, the author(s) utilized [NAME OF TOOL/SERVICE] to [REASON]. Following this tool/service, the author(s) reviewed and edited the content as necessary and take(s) full responsibility for the publication's content.

This declaration does not apply to basic tools for checking grammar, spelling, and references. There is no need to include a statement if there is nothing to disclose.

References:

The author should submit preferably in the Vancouver style. All references must be complete and accurate. The references should be relevant to the study and should refer to the original research sources. The authors, editors, and peer-reviewers should avoid Self-citation and self-interest.

Below are a few examples of references listed in the Vancouver Style:

Vancouver Style

All references should be numbered sequentially [in square brackets] in the text and listed in the same numerical order in the reference section in Vancouver style. Punctuation should be appropriately applied, as mentioned in the examples given above.

Reference Lists:

Different reference formats have different citation rules. See below for some basic format standards.

Journal Article

The required information for a journal article is the author's name, abbreviated journal title, year, publication, volume number, and initial page of cited article, though full pagination is reasonable. It is essential to list all authors if the total number of authors is six or less, and for more than six authors, use three authors and then et al. (the term "et al." should be in italics). Journal abbreviations should follow the Index Medicus/MEDLINE. The author must capitalize the first letter of the first word in the title. The rest of the title should be in lower-case, except for proper names.

[1]     Smith SD, Jones, AD. Organ donation. N Engl J Med 2001; 657: 230-5.

[2]     Brown JG. Asphyxiation. Med J Aust 2003; 432:120-4.

Typical Chapter Reference:

[3]     Blaxter PS, Farnsworth TP. Social health and class inequalities. In: Carter C, Peel JR, editors. Equalities and inequalities in health. 2nd ed. London: Academic Press 1976; p. 165-78.

Book Reference:

[4]     Carlson BM. Human embryology and developmental biology. 3rd ed. St. Louis: Mosby; 2004.

Edited Book:

[5]     Brown AM, Stubbs DW, Eds. Medical physiology. New York: Wiley 1983.

Conference Paper and Proceedings:

[6]     Anderson JC. Current status of chorion villus biopsy. In: Tudenhope D, Chenoweth J, editors. Proceedings of the 4th Congress of the Australian Perinatal Society; 1986: Brisbane, Queensland: Australian Perinatal Society; 1987: p. 190-6.

[7]     Harris AH, Editor. Economics and health: 1997: Proceedings of the 19th Australian Conference of Health Economists; 1997: Sep 13-14; Sydney, Australia. Kensington, N.S.W.: School of Health Services Management, University of New South Wales; 1998.

Journal Article on the Internet:

[8]     Aylin P, Bottle A, Jarman B, Elliott, P. Paediatric cardiac surgical mortality in England after Bristol: descriptive analysis of hospital episode statistics 1991-2002. BMJ [serial on the Internet]. 2004 Oct 9;[cited 2004 October 15]; 329:[about 10 screens]. Available from: https://www.bmj.com/content/329/7470/825.full

Book/Monograph on the Internet: 

[9]     Dungworth D, Editor. Iron Age and Roman Copper Alloys from Northern Britain [monograph on the Internet]. Washington: Digital Monograph Series; [cited 1997]: Available from https://intarch.ac.uk/journal/issue2/dungworth_index.html.

Web site/Homepage:

[10]   Aylin P, Bottle A, Jarman B, Elliott, P. Paediatric cardiac surgical mortality in England after Bristol: descriptive analysis of hospital episode statistics 1991-2002. BMJ [serial on the Internet]. 2004 Oct 9; [cited: 15 October 2004]; 329: [about 10 screens]. Available from: sis.nlm.nih.gov/Tox/ToxMain.html.

Journal with Part/Supplement:

If a journal carries continuous pagination throughout the volume, then the issue number can be omitted.

Issue with Supplement:

[11]   Glauser TA. Integrating clinical trial data into clinical practice. Neurology 2002; 58(12 Suppl 7): S6-12.

Volume with Part:

[12]   Abend SM, Kulish N. The psychoanalytic method from an epistemological viewpoint. Int J Psychoanal 2002; 83(Pt 2): 491-5.

Issue with Part:

[13]   Ahrar K, Madoff DC, Gupta S, Wallace MJ, Price RE, Wright KC. Development of a large animal model for lung tumours. J Vasc Interv Radiol 2002; 13(9 Pt 1): 923-8.

Patent:

[14]   Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug.

E-citations:

[15]   Citations for articles/material published exclusively online or in open access (free-to-view) must contain the exact Web addresses (URLs) at the end of the reference(s), except those posted on an author's Web site unless editorially essential, e.g. 'Reference: Available from: URL'.

Figures / Tables / Illustrations (if any):

The authors are expected to submit good-quality figure(s) in PDF, PPT, MS Word, TIFF, or JPEG versions.

Requirement

• Width = 8.5 inches (In-between the required size)
• Height = 11 inches (In-between the required size)

All figures should be in vector scale (except half tone, photograph.)

Chemical Structures:

Chemical structures MUST be prepared in ChemDraw/CDX and provided as a separate file.

Tables:

Data Tables should be submitted in Microsoft Word or Excel format.

• Each table should include a title/caption explaining the details discussed in the table. Detailed legends may then follow.
• Table number in bold font, i.e., Table 1, should follow a title. The title should be in small case with the first letter in caps. 
• Columns and rows of data should be made visibly distinct by ensuring that the borders of each cell are performed as black lines.
• Tables should be numbered in Arabic numerals sequentially in order of their citation in the body of the text.
• Reference cited in both the table and text, please insert a lettered footnote to refer to the numbered reference in the text.
• It is adequate to present data in Tables to avoid unnecessary repetition and reduce the length of the text.
• The author must ensure the citation of each table in the text.
• The author should explain symbols and non-standard abbreviations at the end of the text.
• All references should be numbered sequentially [in square brackets] in the table and listed in the same numerical order in the reference section.

LANGUAGE AND EDITING:

Manuscripts containing language inconsistencies will not be published. Authors should seek professional assistance for correcting grammatical, scientific, and typographical errors before submitting the revised version of the article for publication. 

PROOF CORRECTIONS:

Authors are required to proofread the PDF versions of their manuscripts before submission. To avoid delays in publication, proofs should be checked immediately for typographical errors and returned within 48 hours. 

The corresponding author will be entirely responsible for assuring that the revised version of the manuscript, including all the proposed amendments, permits the endorsement of all the authors of the manuscript.

REVIEWING AND PROMPTNESS OF PUBLICATION

All papers submitted for publication are immediately subjected to preliminary editorial scrutiny by the Editor-in-Chief regarding their suitability. The Editor-in-Chief determines if the manuscript:

• Falls within the scope of the journal and
• Meets the editorial criteria of Lifescience Global Canada Inc. in terms of originality and quality.

Manuscripts that appear suitable are then subjected to double-blind peer-review by, usually three, neutral eminent experts. The services of well-known international experts are sought through invitations to peer-review a submitted manuscript, keeping in view the manuscript's scope and the reviewers' expertise. The anonymity of reviewers ensures objective and unbiased assessment of the manuscript by the reviewers.

Before sending the manuscripts to reviewers, Lifescience Global Canada Inc. asks for consent from potential reviewers about their availability and willingness to review. Correspondence between the editorial office of the journal and the reviewers is kept confidential. The reviewers are expected to provide their reports in a timely fashion since a prompt review leads to the timely publication of a manuscript that is beneficial not only to the authors but also to the scientific community.

The editorial process and peer-review workflow for each journal are taken care of by a team of Senior Editors, Editorial Board Members (EBMs), and dedicated Journal managers who have the required expertise in their specific fields.

Lifescience Global Canada Inc. carries out an independent review of all articles. The reviewers are chosen according to their expertise from our regularly updated referee database.

The Editors may recommend acceptance, revision, or rejection of a manuscript based on reviewer comments.

Reviewer's comments may be categorized as:

• Requires minor changes
• Requires major changes
• Rejected but may be resubmitted
• Rejected with no resubmission

Lifescience Global Canada Inc. requests not to have the manuscripts peer-reviewed by those experts who may have a competing interest with the author(s) of a submitted manuscript. Editors can't be aware of all competing interests; therefore, it is assumed that the reviewers would inform the Editor-in-Chief/Handling Editor if they notice any potential competing interest during the review of a manuscript.

The authors are usually requested to resubmit the revised paper within five days, and it will then be returned to the reviewers for further evaluation by the publishers. The Editor-in-Chief of the journal is the final authority to accept or reject the manuscript.

• The average time during which the preliminary assessment of manuscripts is conducted is 5 Days
• The average time during which the reviews of manuscripts are conducted 45 Days
• The average time in which the article is published 60 Days

PUBLICATION CHARGES POLICY: 

Lifescience Global Canada Inc. is committed to disseminating research and scholarly publications as widely as possible. It supports the principle that 'the study results that have been publicly funded should be freely accessible in the public domain. Therefore, it encourages researchers to make their research available through Open Access (OA).

Open access publishing is not without costs. Lifescience Global Canada Inc. provides open access publications partly pay the expenses of journal production, online hosting, and archiving from authors and their research supporters by charging a publication fee for each article they publish. For further details please visit: PUBLICATION CHARGES.

SPECIAL FEE WAIVERS:

Lifescience Global Canada Inc. offers waivers and discounts to those corresponding authors: who are based in low-income countries. 

50% FEE concession to authors from any of the below countries, which the World Bank classified as Low-income economies as of 2021. For further details please visit FEE WAIVERS

PLAGIARISM PREVENTION

Lifescience Global Canada Inc. practices the iThenticate software, which detects instances of overlapping and similar text in submitted manuscripts. This software controls content against a database of periodicals, the Internet, and an extensive article database. It generates a similarity report, highlighting the percentage overlap between the uploaded article and the published material. For further details please visit: PLAGIARISM PREVENTION

Lifescience Global Canada Inc. strictly follows the COPE guidelines to detect plagiarism; for more clear insight, authors may refer to flowcharts provided by COPE.

APPEALS AND COMPLAINTS:

Generally, the editorial decisions are not reverted. Authors who think that their manuscript was rejected due to a misunderstanding or mistake may seek an explanation for the decision. Appeals must give sound reasoning and compelling evidence against the criticism raised in the rejection letter. A difference of opinion, interest, novelty, or suitability of the manuscript for the journal will not be recognized as an appeal. The EIC and other relevant editors will consider the request, and the decision after that taken by the journal will be deemed final. Acceptance of the manuscript is not guaranteed even if the journal agrees to reconsider the manuscript. The reconsideration process may involve previous or new reviewers or editors and substantive revision.

Authors who wish to make a complaint should refer them to the Editor-in-Chief of the journal concerned. Lifescience Global Canada Inc. is constantly striving to improve its publication practices. If you are not satisfied with any procedure of the processing of your manuscript, then please let us know at the following e-mail address with full details:

For assistance, please contact: This email address is being protected from spambots. You need JavaScript enabled to view it.. For complaints, please contact: This email address is being protected from spambots. You need JavaScript enabled to view it..

REPRINTS:

Lifescience Global Canada Inc. provides excellent professionally printed reprints. The minimum limit of reprint orders are 100 copies.

PRINTED COVERS:

Printed covers are available at extra cost.

For further details, please visit: This email address is being protected from spambots. You need JavaScript enabled to view it.

PERMISSION FOR REPRODUCTION:

Published/reproduced material should not be included unless you have obtained written permission from the copyright holder. 

For obtaining permission for reproducing any material published in an article by Lifescience Global Canada Inc. This email address is being protected from spambots. You need JavaScript enabled to view it. for consideration.

CONFERENCE PROCEEDINGS:

For proposals to publish conference proceedings in this journal, please contact us at e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it..